Noelle Cloven

2.3k total citations · 1 hit paper
30 papers, 694 citations indexed

About

Noelle Cloven is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Noelle Cloven has authored 30 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Reproductive Medicine, 18 papers in Oncology and 9 papers in Obstetrics and Gynecology. Recurrent topics in Noelle Cloven's work include Ovarian cancer diagnosis and treatment (21 papers), PARP inhibition in cancer therapy (14 papers) and Endometrial and Cervical Cancer Treatments (9 papers). Noelle Cloven is often cited by papers focused on Ovarian cancer diagnosis and treatment (21 papers), PARP inhibition in cancer therapy (14 papers) and Endometrial and Cervical Cancer Treatments (9 papers). Noelle Cloven collaborates with scholars based in United States, Canada and Denmark. Noelle Cloven's co-authors include Melissa A. Geller, Bradley J. Monk, Angeles Alvarez Secord, Ursula A. Matulonis, Kathleen N. Moore, Mihaela Cristea, Gini F. Fleming, David S. Miller, Amit M. Oza and Jonathan S. Berek and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Noelle Cloven

28 papers receiving 669 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019 377 citations Kathleen N. Moore, Angeles Alvarez Secord et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Noelle Cloven

Since Specialization

Citations

This map shows the geographic impact of Noelle Cloven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noelle Cloven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noelle Cloven more than expected).

Fields of papers citing papers by Noelle Cloven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noelle Cloven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noelle Cloven. The network helps show where Noelle Cloven may publish in the future.

Co-authorship network of co-authors of Noelle Cloven

This figure shows the co-authorship network connecting the top 25 collaborators of Noelle Cloven. A scholar is included among the top collaborators of Noelle Cloven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noelle Cloven. Noelle Cloven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1121P Rinatabart sesutecan (Rina-S®) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL™-01 2025 ·Annals of Oncology ·Noelle Cloven, Ira Winer, Eric Lee, Lyndsay Willmott, Jason A. Call, (unknown), (unknown), Andrew Jewell, (unknown), Leigh G. Seamon, Joseph Buscema, Michael Allen Gillespie, (unknown), Teng Jin Ong, Edward Kavalerchik, Dominic Richardson	0
2	Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study. 2025 ·Journal of Clinical Oncology ·Ira Winer, Noelle Cloven, Debra L. Richardson, Lyndsay Willmott, Justin Call, (unknown), Gottfried E. Konecny, Andrea Jewell, Cara Mathews, Leigh G. Seamon, Joseph Buscema, Nurgul Kilavuz, Michael Allen Gillespie, Ibrahima Soumaoro, (unknown)	0
3	A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). 2025 ·Journal of Clinical Oncology ·Angeles Alvarez Secord, (unknown), Michael J. Sundborg, Destin Black, David Starks, Edwin Alvarez, David R. Spigel, Noelle Cloven, (unknown), Anton Melnyk, William E. Winter, Michael McCollum, Ibrahima Soumaoro, Yan Liu, Christian Marth, (unknown)	1
4	Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial. 2024 ·Journal of Clinical Oncology ·(unknown), Trine Lembrecht Jørgensen, Destin Black, David Cibula, Lucy Gilbert, Antonella Savarese, Matthew A. Powell, (unknown), Sarah Gill, Bradley J. Monk, Nicole Nevadunsky, Kari L. Ring, Noelle Cloven, Iwona Podzielinski, Tashanna Myers, Christine Dabrowski, Shadi Stevens, Lyndsay Willmott, Mansoor Raza Mirza	1
5	EV257/#1106 Upgrade: phase 1 trial of the NaPi2b-directed dolaflexin antibody drug conjugate UpRi in combination with carboplatin in patients with platinum-sensitive ovarian cancer (PSOC) 2024 ·Claire F. Friedman, Charles Anderson, John P. Hays, Nehal J. Lakhani, Joseph Buscema, Erika Hamilton, Sara Taylor, (unknown), Noelle Cloven, (unknown), (unknown), (unknown), Theresa L. Werner	1
6	PO001/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA/REC) 2024 ·Noelle Cloven, Henrik Roed, Lucy Gilbert, Zoltán Novàk, Mitchell I. Edelson, Antonella Savarese, Kari L. Ring, Martina Gropp‐Meier, (unknown), (unknown), Sara Bouberhan, Floor Backes, Robert Coleman, (unknown), Alberto A. Mendivil, Solomon J. Lubinga, (unknown), Kateryna Chepynoga, Matthew A. Powell, (unknown)	1
7	#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial 2023 ·Dana M. Chase, Line Bjørge, Robert L. Coleman, (unknown), Eirwen M. Miller, Roberto Angioli, Cara Mathews, Lars Hanker, Michael Teneriello, Anna K.L. Reyners, Matthew A. Powell, Lucy Gilbert, Noelle Cloven, Sarah Gill, Bradley J. Monk, Bhavana Pothuri, (unknown), (unknown), (unknown), Mansoor Raza Mirza	2
8	LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) 2023 ·Annals of Oncology ·(unknown), Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Cloven, Carolyn Y. Muller, David Bender, Richard G. Moore, (unknown), Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Michael E. Carney, Angeles Alvarez Secord, (unknown), (unknown)	2
9	749P Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial 2023 ·Annals of Oncology ·Giorgio Valabrega, Matthew A. Powell, Sakari Hietanen, Eirwen M. Miller, (unknown), Robert W. Holloway, (unknown), Tashanna Myers, (unknown), Kathryn P. Pennington, Lucy Gilbert, (unknown), Larry J. Copeland, Radhika Gogoi, Iwona Podzielinski, Noelle Cloven, Oren Meyers, (unknown), Mansoor Raza Mirza, Destin Black	3
10	MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). 2022 ·Journal of Clinical Oncology ·Leslie M. Randall, David M. O’Malley, Bradley J. Monk, Robert L. Coleman, Stéphanie Gaillard, Sarah F. Adams, Linda Duska, Fabio Cappuccini, Heather Dalton, Robert W. Holloway, Marilyn Huang, Hye Sook Chon, Noelle Cloven, Adam C. ElNaggar, Roisin E. O’Cearbhaill, Steven Waggoner, Zebin Wang, Eric Zhi, (unknown), Panagiotis A. Konstantinopoulos	10
11	Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement 2021 ·Gynecologic Oncology ·(unknown), Israel Zighelboim, Noelle Cloven, Jenna Marcus, Robert L. Coleman, Amer Karam	8
12	738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial 2021 ·Annals of Oncology ·(unknown), Bradley J. Monk, Samuel Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie‐Lacourtoisie, Noelle Cloven, Elena Ioana Braicu, Amit Agrawal, Andrés Redondo, Ruchit Shah, (unknown), (unknown), Dhiraj Gupta, (unknown), David M. O’Malley, Andrew Martin	5
13	818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study 2020 ·Annals of Oncology ·Aikou Okamoto, Gini F. Fleming, Michael A. Bookman, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Noelle Cloven, Takayuki Enomoto, David M. O’Malley, Linda Van Le, Krishnansu S. Tewari, Joyce N. Barlin, William H. Bradley, Kathleen N. Moore, John K. Chan, Meijing Wu, (unknown), Minh H. Dinh, Robert L. Coleman, Carol Aghajanian	2
14	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. 2020 ·Journal of Clinical Oncology ·Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Cloven, Carolyn Y. Muller, David Bender, Richard G. Moore, (unknown), Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Michael E. Carney, Angeles Alvarez Secord, Katherine Moxley, Michael A. Bookman	45
15	810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 2020 ·Annals of Oncology ·Bhavana Pothuri, Sileny Han, (unknown), Florian Heitz, Robert A. Burger, Lydia Gaba, Linda Van Le, (unknown), David Bender, Jacob Korach, Noelle Cloven, Philippe Follana, J.F. Baurain, Carmela Pisano, Ulla Peen, Johanna Mäenpää, (unknown), (unknown), Antonio González-Martı́n, Bradley J. Monk	5
16	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial breakdown → 2019 ·The Lancet Oncology ·Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, B.J. Rimel, Daniela Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk	377
17	Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer 2019 ·Gynecologic Oncology ·Ursula A. Matulonis, Bradley J. Monk, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, (unknown), Katarina Luptakova, Sebastien Hazard, Kathleen N. Moore	6
18	In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer 2004 ·Gynecologic Oncology ·Noelle Cloven	55
19	The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer 2004 ·Gynecologic Oncology ·(unknown), (unknown), Noelle Cloven, P J Morris	27
20	Management of Ovarian Cancer in Patients Older Than 80 Years of Age 1999 ·Gynecologic Oncology ·Noelle Cloven, Alberto Manetta, Michael L. Berman, Matthew F. Kohler, (unknown)	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact